| Catalog No. | HW541026 |
|---|
| Species reactivity | Human |
|---|
| Applications | ELISA, Functional assay, Research in vivo |
|---|
| Isotype | Fusion - [IL15RA (interleukin 15 receptor subunit alpha, CD215, IL-15RA)]2 - IGHG1 Fc (Fragment constant) |
|---|
| Expression system | Mammalian Cells |
|---|
| Target | IL15, IL-15, Interleukin-15 |
|---|
| Endotoxin level | Please contact the lab for this information. |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G purified from cell culture supernatant. |
|---|
| Accession | P40933 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS, pH 7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
|---|
| Alternate Names | ALT-803(=inbakiceptINN11029([IL15RA]2-Fc)incomplex1:2withnogapendekinalfaINN11157(IL15D72)), [IL15RA]2-Fc, 2135939-52-3 |
|---|
| Background | Inbakicept is a dimeric human IL-15 receptor alpha (IL-15 Ra) sushi domain/human IgG1 Fc fusion protein and is an IL-15 superagonist complex. Inbakicept is able to form complex N-803 (Nogapendekin alfa inbakicept) with the IL-15 antibody Nogapendekin alfa in a 1:2 ratio. N-803 mimics the function of IL-15 and amplifies anti-CD20 mAb-mediated NK cell responses and antibody-dependent cellular cytotoxicity (ADCC). N-803 also increases degranulation and IFNγ production in cells.
• Exercise-induced engagement of the IL-15/IL-15Rα axis promotes anti-tumor immunity in pancreatic cancer., PMID:35660135
• Interleukin 15: A key cytokine for immunotherapy., PMID:27325459
• IL-15 in the Combination Immunotherapy of Cancer., PMID:32508818
• IL-27 enhances IL-15/IL-18-mediated activation of human natural killer cells., PMID:31277710
• Interleukin-15 in autoimmunity., PMID:32919253
• Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers., PMID:39604730
• An engineered concealed IL-15-R elicits tumor-specific CD8+T cell responses through PD-1-cis delivery., PMID:36165896
• IL-15, gluten and HLA-DQ8 drive tissue destruction in coeliac disease., PMID:32051586
• Engineering NK-CAR.19 cells with the IL-15/IL-15Rα complex improved proliferation and anti-tumor effect in vivo., PMID:37818365
• Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy., PMID:34797911
|
|---|
| Note | For research use only. Not suitable for clinical or therapeutic use. |
|---|
